KR20150047992A - Compositions for preventing and curing Scuticocilliatosis scutica in a cultivated flounder - Google Patents

Abstract

The present invention relates to a composition for preventing and treating a scutica disease caused by scuticocilliatosis and, more specifically, to a composition for treating and preventing protozoal intestinal diseases of fish, including quaternary ammonium salt and bronopol (2-bromo-2-nitropropane-1,3-diol) as an active ingredient.

Description

Technical Field [0001] The present invention relates to a composition for preventing and treating scuticacid disease in flounder,

[0001] The present invention relates to a composition for controlling squid chicken disease, and more particularly, to a composition for controlling and treating squid chick disease of flounder.

Sikuchikashi is mainly caused by the flounder that is cultured in the aquaculture tank, and it causes the most serious damage in the domestic flounder culture in the 1990s. The causative agent is Sukitika, and the Sukitika is the parasitic cell of the flounder (lower layer) It is a disease mainly caused by ulcers. Recently, about 20 species of Sukuchikaku can be caused by Sukuchikashi, especially in domestic cultured flounder species are known as Philasterides dicentrarchi, Miamiensis avidus, and Uronema marinum are known. Infected flounder leads to anemia, weight loss, body color change, enteritis, mucus hypersecretion, scaly loss, bleeding or shrinking white spots, skin necrosis and mortality. Infected flounder leads to lethal outbreaks with long term specific pathological responses such as infection organs, brain, eye, muscle, gill, liver, kidney, bowel and stomach. Sukuchaku belongs to the protozoa of the protozoa. This is a water droplet, 20 ~ 40㎛ in size, has cilia in the whole body, and actively in water. There is a cell sphere at one end of the trunk. This larvae are not original parasitic life but are protozoan that exist in the nail bottom or wall of aquarium. In the production of seedlings, it causes massive mutilation of the flounder by mass feeding or overdosing. It is not only caused by the body's flesh and fins, but also by the kidneys, blood vessels and brain tissues. Unlike fish parasites, it is invasive to the brain tissue through the blood vessels and is parasitic. It is reported that most flounder is killed by destruction of plastic connective tissue. The period of development is mainly from April to late June. When an infection occurs, it is a priority measure to avoid the smell and to remove the organic material from the bottom of the water tank. When it is parasitized on the outside such as the body surface, the gills and the fins, 100% It is easy to get rid of it, but what is parasitized in the brain is known to be irreversible. Also, its use was banned due to toxic components of formalin. In order to prevent the above diseases, formalin and other toxic or irritating substances such as hydrogen peroxide, stabilized chlorine, malachite green, formaldehyde, and sulfur are used to cause problems in safety of consumers and fishes. Therefore, in order to solve this problem, studies on the insecticidal action of Sucutica insecticides using weakly toxic components have been conducted.

Korean Patent No. 0823558 (aquatic insecticidal insecticide of fish), Korean Patent No. 0937037 (an antimicrobial composition for an antiseptic composition containing vitamin B1 with improved stability and water solubility, Korean Patent No. 0784917 (antimicrobial composition for antibacterial and microorganism-causing microorganisms containing vitamin B1 with improved stability and water solubility), Japanese Patent No. 4820662 (Japanese Patent Application No. 4820662 Korean Patent No. 0373147 (therapeutic agent for squid cichorific infections), Japanese Patent No. 3882939 (method for treating and preventing scurvy of fish), and the like.

However, the composition for controlling and treating scurvy disease is still in an early stage. Accordingly, the present invention relates to a composition for controlling and treating squid chick diseases of the flounder, and it is intended to provide a composition for controlling a squid squid, which is a kind of ciliates causing parasitism in a flounder, and a method of controlling the same The purpose. However, these problems are exemplary and do not limit the scope of the present invention.

According to one aspect of the present invention, there is provided a composition comprising: a first composition comprising a mucoadhesive agent; And

A kit for treating a prostatic disease of a fish comprising a second composition comprising an antimicrobial agent is provided.

In the kit, the first composition may be a kit in which the mucolage remover is dissolved in purified water, and the second composition is a solution in which the antimicrobial agent is dissolved in purified water.

In the kit, the mucolytic agent may be a surfactant.

In the kit, the surfactant may be an anionic surfactant, a cationic surfactant, or a nonionic surfactant.

In the kit, the cationic surfactant may be a quaternary ammonium salt.

In the kit, the quaternary ammonium salt may be a mixture of a benzalkonium salt and a dialkyldimethylammonium salt.

In the kit, the second composition may further comprise a dye.

In the kit, the antimicrobial agent may be a kit that is an antiprotozoan agent, an antibacterial agent, or an antifungal agent.

The kit of any preceding claim, wherein the antigenic aqueous formulation is selected from the group consisting of metrodinazole, eflornithine, furazolidone, melarsoprol, ornidazole, pyrimethamine, ), Tinidazole, paromycine sulfate, hydroxychloroquine, iodoquinol, or pentamidine.

The kit according to claim 1, wherein the antibacterial agent is selected from the group consisting of tetracycline, penicillin, doxycycline, ciprofloxacin, azithromycin, erythromycin, streptomycin, gentamicin, vancomycin, cephalosporin, chloramphenicol, .

According to one aspect of the present invention, there is provided a method of removing mucus from a fish, such as fish gills and skin, And a step of treating the fish-breeding tank with an antimicrobial agent, wherein the step of removing the protist organism comprises the step of treating the fish-breeding tank with an antimicrobial agent.

In the above-mentioned treatment and prevention method, the step of treating the mucolytic agent after the mucosubstance removal step and the step of removing the mucolytic agent by exchanging the water after the mucolytic agent is added to the water tank may be a treatment and prevention method of the protozoan disease of fish.

In the above-mentioned treatment and prevention method, the method may further include a step of removing water after the step of removing the protist organisms to remove the antimicrobial agent.

Further, in the above-mentioned treatment and prevention method, the fish may be infected with Scutica protozoa.

According to another aspect of the present invention, there is provided a composition for treating and preventing a prostatic disease of a fish containing bronopole as an active ingredient.

According to another aspect of the present invention, there is provided a method for treating and preventing a protozoal disease in a fish, comprising treating a pharmaceutically effective amount of bronopol in a water tank.

The composition according to an embodiment of the present invention may be administered to a fish tank in which the fish is inhabited, orally or by local administration to the infected fish.

The pharmaceutically effective amount of the composition according to an embodiment of the present invention may vary from about 1 to 2000 ppm, may range from 10 to 1000 ppm, and may range from about 50 to about 1000 ppm, depending on the type of fish, age, 500 ppm.

The present inventors have found that it is difficult to control the cause of refractory fish diseases such as squid chickens, because these squid chickens live in the mucosal layer covering the surface of the gills and the gills of fishes, and the antimicrobial agent is not properly transmitted to these squid chickens It is not possible to do so.

In order to prove the above hypothesis, the present inventors firstly applied a quaternary ammonium aqueous solution (a kind of a surfactant capable of removing the gills and the mucosal layer on the surface of the body surface) to primary treatment After the lapse of a predetermined period of time, the aqueous quaternary ammonium solution is removed (Step 1), the aqueous solution of bronopol that is a kind of antimicrobial agent capable of removing the squid cuculars is treated in the water tank, (Step 2), which was repeated once a day for several days. As a result, it was confirmed that the wound of the fish infected with Sukuchika can be cured.

Therefore, the two-step treatment method for removing infectious protists by first treating the mucolytic agent according to the present invention to remove fish gills and the mucous layer of the body surface, and then secondarily treating the antimicrobial agent, It is very effective in the treatment and prevention of diseases caused by infectious microorganisms living in the mucous layer.

In one embodiment of the present invention, specific quaternary ammonium salts such as benzalkonium chloride and dialkyldimethylammonium chloride as the mucolytic agent and zerobronophile as an antimicrobial agent were used, but in addition to these, other secondary amines, 3 (SDS), Triton X-100, NP-40, polyoxyethylene glycol, polyoxypropylene glycol, linear alkylbenzenesulfonate, alpha-olefins, An alkyl sulfonate, an alkyl sulfonate, an alkyl sulfate ester salt, a polyoxyethylene alkyl ester sulfate, a secondary alkane sulfonate, an alpha sulfo fatty acid ester salt dialkyldimethylammonium salt, an imidazolium salt, an alkyldimethylbenzylammonium salt, Alkyldimethylamine oxide, fatty acid alkanolamide, alkylpolyglucoside, dioxyethylene alkylpolyphenyl ether, alkylbetaine, A variety of surfactants such as phobetaine and various surfactants such as boric acid, chlorohexidine gluconate, polyhexanide, nonpona azole, butoconazole, albaconazole, benzoic acid, cyclopirox ciclopirox, or flucytosine may be used as alternatives.

According to one embodiment of the present invention as described above, the mortality rate of infected squid chickens can be effectively reduced, and the present invention is very useful as a composition and method for prevention and treatment of squid chick infections. Of course, the scope of the present invention is not limited by these effects.

1 is a graph showing the stability test results of a therapeutic agent A solution containing benzalkonium chloride.
2 is a graph showing the stability test results of the therapeutic agent B solution containing bronopol.
FIG. 3 is a graph showing the results of the efficacy test on the therapeutic agents A and B solutions containing bronopol.
Fig. 4 is a photograph showing the appearance of scutchica according to the treatment with solution B for the efficacy test of the therapeutic agent B solution containing bronopol. Fig.
Fig. 5 is a photograph of a flounder in which the symptoms of infection with Sukuzaka were alleviated by treatment with a solution B of treatment agent B together with a treatment agent A solution using Sukikica infected flounder.
Fig. 6 is a photograph of a flounder in which the symptom of infection with Shikuchika was alleviated by a single treatment of the treatment agent B solution using a squid chick infected flounder.
7 is a graph showing the mortality rate over time for 11 days after treatment of the therapeutic agent A solution containing benzalkonium chloride infected with scutchica in a farm and the therapeutic agent B solution containing bronopolol.

Definition of Terms:

Quaternary ammonium salt refers to an ammonium salt (NR1R2R3R4 + A-) in which four functional groups are attached to a nitrogen atom in place of hydrogen, wherein R1 to R4 each independently represent an alkyl or aryl group, and A- represents an anion ), The A-anion may be a halogen ion, and the halogen ion may be fluoride, chloride, bromide, or iodide. It is mainly used as a cleaning agent.

Dialkyl dimethyl ammonium salt: a kind of the quaternary ammonium salt, an ammonium salt having two methyl groups and two alkyl groups attached to a nitrogen atom, and the alkyl group usually has 10 carbon atoms

Benzalkonium salt: An alkyl dimethyl benzyl ammonium salt, which is a kind of quaternary ammonium salt, in which one benzyl group, two methyl groups and usually eight to eighteen carbon atoms are attached to the nitrogen atom . It is known that it has antibacterial function which is less toxic to human body.

Bronopol: a compound having the formula C ₃ H ₆ BrNO ₄ and having the formula: 2-bromo-2-nitropropane-1,3-diol according to the IUPAC nomenclature and is usually an antimicrobial agent and preservative It has been used:

.

.

Specific embodiments of the invention:

Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples. It should be understood, however, that the invention is not limited to the disclosed embodiments and examples, but may be embodied in many different forms and should not be construed as limited to the exemplary embodiments set forth herein. It is provided to fully inform the scope of the invention to the person.

Example 1: Composition of Solutions A and B of Therapeutic Agents

In the present invention, the therapeutic agent for scutichaca disease is designed to kill the scuticaccharide while synergizing with each of the other two drugs (solutions A and B).

1-1: Therapeutic Agent Solution A

The therapeutic agent solution A was prepared for removing the mucous layer of the gills of the fish. Various types of surfactants are used as a mucolytic agent for removing the mucus layer. In one embodiment of the present invention, a quaternary ammonium salt having an antiseptic activity is included, Dialkyldimethylammonium chloride and benzalkonium chloride were used as super ammonium. The quaternary ammonium salt is generally used for cleaning or disinfecting purposes. In particular, Flexibacter sp. , Is used to treat bacterial gill diseases caused by infection with the same sliding bacteria. When infected with this disease, the germs multiply in the mucous membrane, and this stimulation of the gill epithelium layer is known to further increase mucus secretion.

1-2: Therapeutic agent B solution

The Therapeutic Agent B solution was designed for the removal of the ciliate, Scuticaci, in one embodiment of the present invention, a new environmentally friendly chemical, Bronopol (British Pharmacopoeia) was used. The bloopol has been reported to have the ability to inhibit Gram-negative sebaceous glands in the past, and is said to be relatively non-toxic to the human body, shampoo. In particular, it has been reported that when long-term exposure to Velvet infection caused by Amyloodinium ocellatum results in the formation of dinospores as bilateral caps (dinospores) It is known that it exhibits a potent insecticidal / cytotoxic effect on free-range larvae (tomonts, cysts, and theronts) in hundreds of freshwater fish caused by infection with Ichthyophthirius multifiliis . The short - term treatment (about 30 minutes) at 20, 50 and 100 mg / L, which are high dose concentrations, markedly delayed the larvae of the free - floating stage (cones, On the other hand, survival of infectious larvae (theronts) was significantly reduced by prolonged administration at low concentration (eg 1 mg / L).

The inventors of the present invention have hypothesized that the main infecting sites of Sukuchikari are the gills and scales and that the control of Sukuchakus infected with gills is the most difficult, Respectively. First, the solution of the drug A capable of removing the mucus from the flounder gill was pre-treated to remove the mucilage present in the flounder gill, and then the solution of the drug B capable of inhibiting the occurrence of adult fungi was killed It was predicted that treatment and prevention of squid cichotic infection would be possible. Therefore, it was verified through experimental examples that the sequential treatment method of the solution A and the solution B is effective for the treatment and prevention of the actual infection with scuticaccharide.

Experimental Example 1: Safety (LCt50) test

For the stability test (LCt ₅₀ , LCt: Lethal Concentration time) of the present invention, as shown in Table 1, a healthy flounder ( Paralichthys olivaceus ) 9 to 10 g body weight and 8-12 cm- Ten dogs were used according to each experimental condition. The specifications of the fish were the same and were carried out in a water tank containing 30 L of seawater.

Treatment capacity of flounder and solution for stability test Test group Treatment capacity Mari (US) number
Therapeutic Agent A Solution Safety 30ppm 10 50 ppm 10 100ppm 10 A control group No treatment 10
Therapeutic Agent B Solution Safety 300ppm 9 600ppm 9 1,000ppm 9 B control No treatment 9 system 76

As shown in Table 2, the results of the fluke stability test for the therapeutic agent A solution were as follows: the solution A was stored for up to 15 hours at 30 ppm, and one died at 12 hours and 13 hours after 50 ppm, After the lapse of 14.5 hours, 5 mice died and all the remaining untreated mice died after 15 hours. After 6 hours at 100 ppm, 4 animals died and after 8 hours, all the other animals died. There was no mortality in the untreated group of control A solution. FIG. 1 is a graph showing the results of the stability test for the therapeutic agent A solution, and is a graph showing the number of flounder in the flounder according to the passage of time when the solution A was treated for each dose.

A solution and survival rate of flounder Elapsed time (hr)
Treatment concentration Early
2
hr 4
hr 6
hr 6.5
hr 7
hr 8
hr 12
hr 13
hr 14
hr 14.5 hr
15
hr A-30 ppm 10 10 10 10 10 10 10 10 10 10 10 10 A-50 ppm 10 10 10 10 10 10 10 9 9 5 5 0 A-100 ppm 10 10 10 6 6 One 0 0 0 0 0 0 No treatment 10 10 10 10 10 10 10 10 10 10 10 10

As shown in Table 3, the results of the flounder stability test for the therapeutic agent B solution were as follows. One solution died after 28 hours at 300 ppm, one died after 18 hours at 600 ppm, and after 22 hours 8 dogs, 4 dogs after 26 hours, and 6 dogs after 28 hours. At 1000 ppm, 2 liters died after 14 hours and 15 hours, 8 died after 18 hours, and all remaining untreated after 20 hours. There was no mortality in the untreated group of control B solution. FIG. 2 is a graph showing the number of live flounder flocks according to time for each treatment capacity of solution B; FIG. After treating the treated drug solutions A and B with the dead dose, treat each treatment dose group and obtain LCt50.

LCt ₅₀ was determined using conventional methods and the therapeutic agent A solution was calculated as LCt ₅₀ at 50 ppm for 14 hours and LCt ₅₀ for 6 hours and 40 minutes at 100 ppm (Reed et al., Am. J. Epidemiol. 27 3): 493-497, 1938).

B solution and survival rate of flounder Elapsed time (hr)
Treatment concentration Early 2 hr 4hr 6hr 7hr 8hr 12hr 13hr 14hr 15hr 18hr 20hr 21hr 22hr 26hr 28hr B-300 ppm 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 9 B-600 ppm 10 10 10 10 10 10 10 10 10 10 9 9 9 8 6 4 B-1,000 ppm 10 10 10 10 10 10 10 10 8 8 2 0 0 0 0 0 No treatment 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10

Treatment agent B solution in 600 ppm in 27 hours LCt _50, 100 ppm 16 hour 40 minutes ₅₀ showed a LCt.

Experimental Example 2: Effectiveness Test

2-1: Comparison of the activity of SQUICACA

As a part of the validity test of the B solution in the present invention, the effectiveness of the B solution according to the mixing of mucus and scutchica was confirmed. Since the mucus of the flounder is to protect by accumulating the Sukusaka layer, the mucus surrounds the Sukusaka area before effectively exterminating the Sukuzaka through the B solution. Therefore, the effect of the activity of the Sukusaka area Respectively. Using a 24-well plate, the mucus collected from the flounder was mixed with seawater at a ratio of 1: 1 and tested by inoculating squid chickens with 10 ⁴ / ml. The mucus - free and mucin - treated flounder were repeated 3 times each. As a result of examining the activity of SQUUZICA according to the mucilage treatment of the flounder using the B solution, the activity of SQUUZICA in the treatment of the solution of B solution at 80 ppm was observed in the treatment without the mucilage of the flounder, Showed the activity of Sukuzaka when treated with 156 ppm of B solution.

2-2: Validation of A and B solutions treated with Sukuchika infected flounder

For the validity test of the solution B of the present invention, as shown in Table 5, a total of 66 squid chickens infected flounder were used, and they were weighed 10 to 15 g, 8 to 12 cm in length, and treated for 8 days . In the following method, 9 flounders were placed in each tank containing 30 L of seawater, and after 6 hours of stabilization, the medicines were treated for each concentration, and the seawater was exchanged after 1 hour of treatment, Except the control group, the aquarium circulated the sea water. The medication was treated daily for 8 days.

The treatment capacity of flounder flounder and solution for the efficacy test Test group Treatment capacity Mari (US) number
A solution effectiveness 20 ppm 30ppm 10 50 ppm 10
B solution effectiveness 300ppm 9 500ppm 9 600ppm 9 Control group No treatment 9 system 66

In the present invention, the therapeutic agent A solution and the solution B were treated for each treatment capacity group, and then their effectiveness was verified. On the day of administration, the general condition is observed every hour from 1 hour to 6 hours after administration. From the next day until the 14th day of the administration, the change of the general condition, the poisoning symptom and the presence of the lethal animal were observed once a day. (Abdominal distension, pinhead, yamum, flexion, etc.), body color (blackening, whitening, mucus secretion, etc.) (General anomalies, anemia, fading, bleeding, defects, etc.), visceral (multiple, bleeding, congestion, abscess, nodule, white, atrophy, hypertrophy, discoloration, . All animals were weighed immediately before dosing and at 7 and 14 days after dosing. Microbiological tests (pathogenetic isolation, identification, and pathogenicity) are carried out in case of suspected scutchica infection and bacterial infection in leprosy gills and skin, and the test group and the control group are compared. In the case of autopsy, the flounder that died during the observation period was lethally lethal and gross abnormality of the internal organs was observed in detail, and organs with gross abnormality were fixed with 10% neutral formalin solution.

The treatment capacity of the solution and the survival flounder Control group 300ppm 500ppm 600ppm Early 9 9 9 9 1 day 9 6 8 7 2 days 8 5 8 6 3 days 7 5 8 6 4 days 6 4 8 6 5 days 5 4 8 6 6 days 3 4 8 6 7 days One 4 8 6 8 days 0 4 8 6

As shown in Fig. 3, in the control group, dead animals died on day 1 after the first day of experiment, and all animals died on the eighth day of experiment. In the 300 ppm treatment group, three animals on the first day of experiment, one animal on the second and third day of experiment, After our death, the four surviving were healed. In the 500 ppm treatment group, one mouse died after the first day of experiment, and all survived and were healed. In the 600 ppm treatment group, 2 mice were observed on the first day and 6 mice died after 1 day on the second day of the experiment. Fig. 4 is a photograph showing the appearance of squid chick according to the B solution treatment for the efficacy test of the therapeutic agent B solution. After observing the shape after treatment with the therapeutic agent B for Sukuzaka, the movement slowed at the beginning of treatment (A) when the time passed, the blister (arrow ①) was observed on the surface of Sukuzaka, (Arrow 2) is observed. In this type of deformed Sukikica, after 30 minutes of treatment, the membrane will die in its complete state (death without modification - arrow ③, death in a deformed state - arrow ④). Fig. 5 is a photograph of a flounder showing validation according to treatment with a therapeutic agent B using a squid chick infected flounder. As shown in Fig. 5, the 300 ppm treated fish showed mild mucinage, but showed complete healing at 26 days after treatment. The 500 ppm treated mushroom showed considerably mucinous mucosa, . The 600 ppm treated fish body was similar to the 300 ppm fish body, but showed almost complete healing from 14 days after treatment. In order to confirm the validity of the treatment with B solution using the infected flounder with squid, we investigated the infection of squid chickens in flounder and dead flounder. The results of the validation according to the B solution treatment using the squid chick infected flounder according to one experimental example of the present invention are as follows. After treatment with Solution B, the infection of squid chickens in flounder and dead flounder was investigated. On the first day after treatment with solution B of the therapeutic agent B, the infection of squid chickens was confirmed in the gills, the fins and the skin / muscle in all experimental specimens including the control group. As a result, In the flounder, it was possible to confirm the infection of the squirrel in the brain. On the second day of treatment, S. aureus infections were detected in the control and 300 ppm treatments, and Sukuzaka infection was not observed in 500 ppm and 600 ppm treatments. In the control group, all of the mice died on the 8th day of treatment, and the infection with Scuccica was confirmed. In the case of 300 ppm treatment, fin and muscle necrosis were observed in dead flounder at 4th day of treatment, but no squid chick infection was observed. The evaluation method for the efficacy test was confirmed by scraping the infected area and decreasing the number of live or dead squirrel in a significant manner, measuring the body weight and measuring the mortality (Table 3, Fig. 4, Fig. 5).

2-3: Validation by treatment of B solution with squid chick infected flounder

After the B solution of the present invention was administered alone, a Sucucica infected flounder of 10 to 15 g body weight and 8 to 12 cm in length was used for the efficacy test. In each tank containing 30 L of seawater, 9 flounders were added and after stabilization for 6 hours, the treatment solution B was treated at 600 ppm, and after 1 hour of treatment, the seawater was exchanged. After that, Respectively. The medication was treated daily for 8 days. As shown in FIG. 6, it was shown that the Sucucica infection was healed by administering the therapeutic agent B solution alone to the naturally infected flounder as described above. However, in the case of treatment with the therapeutic agent B alone, the recovery rate was slower than in the case of the sequential treatment of the therapeutic agent A solution and the therapeutic agent B solution.

Experimental Example 3: Field efficacy test

The field efficacy test of the present invention was carried out on oleic acid (Jeju, Korea) from August 7 to 23, 2012. The treatment solution A was treated with 50 ppm for 30 minutes in flounder of 100-150 g size, B solution was treated at 500 ppm for 1 hour to 1 hour 30 minutes. In field tests, flounder (Paralichthys olivaceus), a test group (n = 10000), and a control group (n = 10000) were used as wild-type animals. The method of administration is as follows. Therapeutic agents Solution A and Solution B were treated once a day for 5 days. In other words, the solution was treated within a maximum of 50 ppm within a period of about 30 minutes and the water was exchanged. Subsequently, the B solution is continuously treated in the same water tank at a maximum of 500 to 600 ppm for about 2 to 3 hours, and the water is exchanged. The observation period was 2 weeks. After the administration, the general condition is observed every hour from 1 hour to 6 hours after the administration on the day of administration. From the next day of dosing to 14 days, changes in general condition, poisoning symptoms, and the presence of dead animals were observed once daily between the control and test groups. During the observation period, the flounder was examined by microbiological test and hemorrhagic lethality, and gross abnormality of the internal organs was examined in detail. Organs with gross abnormality were fixed with 10% neutral formalin solution. After the end of the evaluation, all the weights were measured after disposal. As a result of the experiment of the present invention, the experiment was carried out in a fish tank containing only the fish infected with SQUUZICA. In the treatment period, a lot of fish died during the first week in the tank treated with both the therapeutic agent A and the B solution, Thereafter, it can be seen that the number of pessimists is smaller than that of the water treatment tank not treated with the control treatment tank. This appears to be the result of the stressfulness of the bathing agent during the bathing period, resulting in premature death of the weakened individuals. However, we confirmed that our company showed a significant decrease from 7 days after the battle. FIG. 7 is a graph showing the mortality rate over time for 11 days after treatment with the therapeutic agents A and B solutions. FIG. In the graph of FIG. 7, the red line indicates the group treated with the drug, and the blue line indicates the group not treated with the drug. As shown in Fig. 7, it is expected that the treatment of both the therapeutic agent A and the solution B can help reduce the period of infection of the scutchica.

Claims (16)

A first composition comprising a mucoadhesive agent; And
A kit for treating a prostatic disease of fish, comprising a second composition comprising an antimicrobial agent. The kit according to claim 1, wherein the first composition is a solution in which the mucolytic agent is dissolved in purified water, and the second composition is a solution in which the antimicrobial agent is dissolved in purified water. The method according to claim 1,
Wherein the mucolytic agent is a surfactant. 4. The kit of claim 3, wherein the surfactant is an anionic surfactant or a cationic surfactant. 5. The method of claim 4,
Wherein the cationic surfactant is a quaternary ammonium salt. 6. The kit according to claim 5, wherein the quaternary ammonium salt is a mixture of a benzalkonium salt and a dialkyldimethylammonium salt. The method according to claim 1,
Wherein the second composition further comprises a pigment. The method according to claim 1,
Wherein the antimicrobial agent is an antiprotozoan agent, an antibacterial agent or an antifungal agent. 9. The method of claim 8,
The antigenic veterinary preparation may be selected from the group consisting of metrodinazole, eflornithine, furazolidone, melarsoprol, ornidazole, pyrimethamine, wherein the kit is a tinidazole, paromycine sulfate, hydroxychloroquine, iodoquinol, or pentamidine. 9. The method of claim 8,
Wherein the anti-bacterial agent is tetracycline, penicillin, doxycycline, ciprofloxacin, azithromycin, erythromycin, streptomycin, gentamicin, vancomycin, cephalosporin, chloramphenicol, or bronopol. Removing the mucus from the fish gill by treating the mucolytic agent in a fish rearing tank; And
A method for the treatment and prevention of a protozoal disease of fish, comprising a step of treating the fish rearing tank with an antimicrobial agent. 12. The method of claim 11,
And removing the mucolytic agent by exchanging water after treating the mucolytic agent in the water tank after the mucolytic removal step. 12. The method of claim 11,
Further comprising the step of removing the antimicrobial agent by exchanging water after the step of removing the protist organism. Wherein said fish is infected with a Scutica protozoa. A composition for treating and preventing a prostatic disease of fish containing bronopol as an active ingredient. A method for treating and preventing a prophylactic disease in a fish, comprising treating a pharmaceutically effective amount of bronopol in a water tank.

Images